NUVB Latest Press Releases

-- June 29, 2026 --

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom PRNewswire 8:00 AM

-- June 25, 2026 --

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PRNewswire 11:59 PM

Nuvation Bio Announces Proposed Convertible Senior Notes Offering PRNewswire 7:00 AM

-- May 27, 2026 --

Nuvation Bio to Present at the Jefferies Global Healthcare Conference PRNewswire 4:05 PM

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting PRNewswire 8:00 AM

-- May 13, 2026 --

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer PRNewswire 4:05 PM

-- May 7, 2026 --

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB) PRNewswire 10:56 AM

-- May 6, 2026 --

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer PRNewswire 5:28 PM

-- May 5, 2026 --

Nuvation Bio to Participate in Upcoming Investor Conferences PRNewswire 4:05 PM

-- May 4, 2026 --

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update PRNewswire 4:10 PM

-- April 27, 2026 --

Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers PRNewswire 8:00 AM

-- April 21, 2026 --

/U P D A T E -- Nuvation Bio Inc./ PRNewswire 6:50 PM

Nuvation Bio Announces IBTROZI (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 PRNewswire 6:00 PM

-- April 20, 2026 --

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 PRNewswire 4:05 PM

-- April 7, 2026 --

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm Globe Newswire 10:26 AM

-- April 2, 2026 --

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm PRNewswire 1:19 PM

-- April 1, 2026 --

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo PRNewswire 8:00 AM

-- March 26, 2026 --

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency PRNewswire 4:05 PM

-- March 21, 2026 --

NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm Business Wire 5:15 PM

-- March 17, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB Globe Newswire 5:33 PM

Nuvation Bio to Present Pivotal IBTROZI (Taletrectinib) Data in TKI-Nave and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 PRNewswire 4:35 PM

-- March 13, 2026 --

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm Globe Newswire 9:12 AM

-- March 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB PRNewswire 10:00 AM

-- March 10, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB Globe Newswire 4:03 PM

-- March 6, 2026 --

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm PRNewswire 2:21 PM

-- March 4, 2026 --

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 8:30 AM

-- March 2, 2026 --

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PRNewswire 4:05 PM

-- February 25, 2026 --

Nuvation Bio to Participate in Upcoming Investor Conferences PRNewswire 4:05 PM

-- February 17, 2026 --

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 PRNewswire 4:05 PM

-- February 9, 2026 --

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma Business Wire 8:00 AM